Preferred Label : Sofosbuvir;
MeSH definition : A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B
that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.;
MeSH synonym : 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic
acid isopropyl ester;
MeSH hyponym : GS-7977; PSI 7977; Sovaldi; 7977, PSI; PSI7977; PSI-7977; GS 7977; GS7977;
Wikipedia link : https://en.wikipedia.org/wiki/Sofosbuvir;
Is substance : O;
UNII : WJ6CA3ZU8B;
Origin ID : D000069474;
UMLS CUI : C2976303;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Metaterm(s)
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- See also (suggested by CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B
that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
https://www.has-sante.fr/jcms/p_3299664/fr/sovaldi-sofosbuvir
2021
false
false
false
France
evaluation of the transparency committee
resulting in
registries
Outcome Assessment, Health Care
outcome studies
Sovaldi
Sofosbuvir
---
https://www.has-sante.fr/jcms/p_3224401/fr/sovaldi
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
Sofosbuvir
sofosbuvir
antiviral agents
hepatitis C, chronic
Product containing only sofosbuvir in oral dose form (medicinal product form)
adult
child
adolescent
---
https://www.has-sante.fr/jcms/p_3152658/fr/vosevi
2020
false
false
false
France
sofosbuvir, velpatasvir and voxilaprevir
drug combinations
Sofosbuvir
velpatasvir
voxilaprevir
adult
administration, oral
treatment outcome
insurance, health, reimbursement
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
carbamates
Heterocyclic Compounds, 4 or More Rings
sulfonamides
macrocyclic compounds
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.has-sante.fr/jcms/p_3224423/fr/epclusa
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
sofosbuvir-velpatasvir drug combination
antiviral agents
Product containing only sofosbuvir and velpatasvir in oral dose form (medicinal product
form)
sofosbuvir and velpatasvir
hepatitis C, chronic
adult
adolescent
child
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.has-sante.fr/jcms/p_3152667/fr/epclusa
2020
false
false
false
France
Sofosbuvir
velpatasvir
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
Epclusa
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
---
https://www.has-sante.fr/jcms/p_3152661/fr/sovaldi
2020
false
false
false
France
Sofosbuvir
sofosbuvir
evaluation of the transparency committee
Sovaldi
---
https://www.has-sante.fr/jcms/p_3152635/fr/harvoni
2020
false
false
false
France
Sofosbuvir
treatment outcome
ledipasvir
ledipasvir, sofosbuvir drug combination
adult
adolescent
antiviral agents
drug combinations
hepatitis C, chronic
evaluation of the transparency committee
Harvoni
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
---
https://www.has-sante.fr/jcms/p_3115175/fr/epclusa
2019
false
false
false
France
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
sofosbuvir-velpatasvir drug combination
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni-sofosbuvir/ledipasvir-antiviral-a-action-directe
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni
2018
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
guidelines for drug use
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
adolescent
uridine monophosphate
uridine monophosphate
uridine monophosphate
---
https://www.has-sante.fr/portail/jcms/c_2848084/fr/sovaldi-sofosbuvir-antiviral-a-action-directe
https://www.has-sante.fr/portail/jcms/c_2848084/fr/sovaldi
2018
false
France
French
administration, oral
treatment outcome
insurance, health, reimbursement
drug therapy, combination
antiviral agents
antiviral agents
hepatitis C, chronic
evaluation of the transparency committee
guidelines for drug use
Sofosbuvir
Sofosbuvir
sofosbuvir
adolescent
Chronic hepatitis C genotype 2
Chronic hepatitis C genotype 3
hepatitis C, chronic
ribavirin
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds
---
https://www.has-sante.fr/portail/jcms/c_2817995/fr/vosevi
2017
false
false
false
France
French
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
treatment outcome
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
insurance, health, reimbursement
evaluation of the transparency committee
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Vosevi
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug approval
europe
treatment outcome
product surveillance, postmarketing
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
drug interactions
pregnancy
breast feeding
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
drug evaluation, preclinical
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
NS3-4A serine protease, Hepatitis C virus
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-juin-Recommandations-AFEF-Hepatite-C.pdf
2016
false
false
true
false
France
French
hepatitis C, chronic
practice guideline
severity of illness index
hepatitis C, chronic
antiviral agents
comorbidity
genotype
daclatasvir
ledipasvir
ribavirin
treatment outcome
drug resistance, viral
pregnancy
patient education as topic
liver cirrhosis
liver transplantation
recurrence
renal insufficiency
child
adolescent
drug users
hiv infections
acute disease
Acute hepatitis C
Simeprevir
Sofosbuvir
ledipasvir
ledipasvir, sofosbuvir drug combination
daclatasvir
imidazoles
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
---
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa-sofosbuvir/velpatasvir-association-fixe-d-antiviraux-a-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
drug combinations
Sofosbuvir
Sofosbuvir
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
velpatasvir
velpatasvir
hepatitis C, chronic
adult
guidelines for drug use
sofosbuvir-velpatasvir drug combination
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
drug combinations
---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00329
2016
false
false
false
Canada
French
drug information
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles
---
https://www.ema.europa.eu/medicines/human/EPAR/Epclusa
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
velpatasvir
velpatasvir
drug combinations
Sofosbuvir
Sofosbuvir
antiviral agents
antiviral agents
pregnancy
breast feeding
drug interactions
hepatitis C, chronic
adult
administration, oral
drug therapy, combination
NS-5a protein, hepatitis C virus
enzyme inhibitors
enzyme inhibitors
RNA-Dependent RNA Polymerase
product surveillance, postmarketing
aged
drug evaluation, preclinical
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
NS-5 protein, hepatitis C virus
viral nonstructural proteins
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
---
https://medicalforum.ch/fr/detail/doi/fms.2015.02265/
2015
false
false
false
Switzerland
French
journal article
hepatitis C
antiviral agents
drug therapy, combination
Sofosbuvir
---
Amiodarone - Slow Heart Rate in Patients Taking Amiodarone Together with Harvoni or
Sovaldi and a Direct Acting Antiviral
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/52801a-fra.php
2015
false
false
false
Canada
French
English
pharmacovigilance note
bradycardia
amiodarone
drug interactions
canada
antiviral agents
Sofosbuvir
---
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni-sofosbuvir/ledipasvir-association-fixe-dantiviraux-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
adult
guidelines for drug use
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 3 (organism)
Hepatitis C virus genotype 4 (organism)
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
uridine monophosphate
uridine monophosphate
uridine monophosphate
---
http://www.avisdexperts.ch/videos/view/3182/1/a%3A1%3A%7Bs%3A3%3A%22Tag%22%3Ba%3A1%3A%7Bi%3A0%3Bs%3A8%3A%22MEDECINE%22%3B%7D%7D
2014
false
false
false
Switzerland
French
hepatitis C
drug costs
antiviral agents
antiviral agents
drug combinations
video recording
Sofosbuvir
Sofosbuvir
---
https://www.ema.europa.eu/medicines/human/EPAR/Harvoni
2014
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
adult
hepatitis C, chronic
administration, oral
tablets
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
NS-5b protein, hepatitis C virus
treatment outcome
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
viral nonstructural proteins
uridine monophosphate
uridine monophosphate
uridine monophosphate
---
https://medicalforum.ch/fr/detail/doi/fms.2014.01992/
2014
false
false
false
Switzerland
French
journal article
hepatitis C
antiviral agents
Simeprevir
Sofosbuvir
---
http://www.has-sante.fr/portail/jcms/c_1743036/fr/sovaldi-sofosbuvir-antiviral-a-action-directe
2014
false
false
false
France
French
administration, oral
treatment outcome
hepatitis C, chronic
adult
drug therapy, combination
insurance, health, reimbursement
antiviral agents
antiviral agents
evaluation of the transparency committee
guidelines for drug use
Sofosbuvir
Sofosbuvir
sofosbuvir
---
https://www.ema.europa.eu/medicines/human/EPAR/Sovaldi
2014
false
United Kingdom
French
English
drug approval
europe
treatment outcome
hepatitis C, chronic
adult
administration, oral
antiviral agents
antiviral agents
RNA-Dependent RNA Polymerase
summary of product characteristics
package leaflet
syndication feed
drug evaluation
NS-5 protein, hepatitis C virus
product surveillance, postmarketing
drug monitoring
drug therapy, combination
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
aged
viral nonstructural proteins
Sofosbuvir
Sofosbuvir
sofosbuvir
---
